NYSEMKT: SSYSunlink Health Systems Inc Stock
$0.81-0.04 (-4.71%)
Updated Oct 3, 2024
SSY Price
$0.81
Fair Value Price
N/A
Market Cap
$5.70M
52 Week Low
$0.53
52 Week High
$1.05
P/E
-3.68x
P/B
0.36x
P/S
0.17x
PEG
N/A
Dividend Yield
N/A
Revenue
$32.44M
Earnings
-$1.53M
Gross Margin
39.8%
Operating Margin
-4.72%
Profit Margin
-4.7%
Debt to Equity
0.29
Operating Cash Flow
-$3M
Beta
0.56
Next Earnings
Nov 15, 2024
Ex-Dividend
N/A
Next Dividend
N/A
SSY Overview
SunLink Health Systems, Inc. engages in the provision of healthcare products and services. The company is headquartered in Atlanta, Georgia and currently employs 1,376 full-time employees. The firm's segments include Healthcare Facilities, Specialty Pharmacy, and Corporate and Other. Its Specialty Pharmacy segment is operated through its subsidiary, SunLink ScriptsRx, LLC (Scripts). As of June 30, 2016, its Healthcare Facilities segment subsidiaries owned and operated Trace Regional Hospital, which is a 84 bed community hospital and Floy Dyer Manor Nursing Home, which is a 66 bed nursing home in Mississippi, and Gilmer Nursing Home, which is a 100 bed nursing home in Georgia. As of June 30, 2016, the Specialty Pharmacy Segment subsidiary operated a specialty pharmacy business in Louisiana with four service lines. Its Specialty Pharmacy segment operates service lines, including retail pharmacy products and services; institutional pharmacy services; specialty pharmacy services, and durable medical equipment services.
Zen Score
–
Industry Average (21)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SSY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SSY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SSY is good value based on its book value relative to its share price (0.36x), compared to the US Pharmaceutical Retailers industry average (0.57x)
P/B vs Industry Valuation
SSY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SSY due diligence checks available for Premium users.
Be the first to know about important SSY news, forecast changes, insider trades & much more!
SSY News
Valuation
SSY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.68x
Industry
-1.8x
Market
26.22x
SSY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.36x
Industry
0.57x
SSY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SSY's financial health
Profit margin
Revenue
$7.9M
Net Income
$4.3M
Profit Margin
54.2%
SSY's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
SSY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$20.6M
Liabilities
$4.6M
Debt to equity
0.29
SSY's short-term assets ($15.66M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SSY's short-term assets ($15.66M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SSY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SSY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$386.0k
Investing
$6.3M
Financing
$0.0
SSY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SSY vs Pharmaceutical Retailer Stocks
Sunlink Health Systems Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.